Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

DOI Full Paper Access

150

Citations

27

References

2023

Year

Ari M. Vanderwalde, Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey A. Sosman, Alexandra P. Ikeguchi,

Nature Medicine

MedicineMelanomaPharmacologyImmunologyImmune Checkpoint InhibitorPharmacotherapyTumor TargetingCancer TreatmentImmunotherapyOncologyRandomized Phase 2

References

	Year	Citations

Page 1

Page 1